faldaprevir faldaprevir faldaprevir was an experimental drug for the treatment of hepatitis c (hcv). it was being developed by boehringer-ingelheim and reached phase iii clinical trials in 2011. boehringer announced in 2014 that it would not pursue approval of the drug any more because of better hcv treatments having become available. faldaprevirclinical dataother namesbi 201335routes ofadministrationby mouthatc codej05ap04 (who) legal statuslegal status abandoned identifiers iupac name n--3-methyl-l-valyl-(4r)-4-(oxy)-n--l-prolinamide cas number801283-95-4pubchem cid42601552drugbankdb11808chemspider26327117unii958x4j301achemblchembl1241348comptox dashboard (epa)dtxsid20230084 chemical and physical dataformulac40h49brn6o9smolar mass869.83 g·mol−13d model (jsmol)interactive image smiles cc(c)c(=o)nc1nc(cs1)c2cc(c3ccc(c(c3n2)br)oc)o4c(n(c4)c(=o)(c(c)(c)c)nc(=o)oc5cccc5)c(=o)n6(c6c=c)c(=o)o inchi inchi=1s/c40h49brn6o9s/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32h,1,9-12,15,17-18h2,2-7h3,(h,44,53)(h,46,49)(h,51,52)(h,43,45,48)/t21-,23-,27+,32-,40-/m1/s1key:llgdptdzovkfdu-xuhjstdzsa-n mechanism of action faldaprevir is a hepatitis c virus protease inhibitor. studies faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir. data from the sound-c2 study, presented at the 2012 aasld liver meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in hcv genotype 1b patients.